在U-PGx PREPARE研究中招募的患者的基于小组的药物遗传学指导治疗的跨国成本效益分析
Vasileios Fragoulakis1, Jesse J Swen2, Margarita-Ioanna Koufaki1,3
1The Golden Helix Foundation, London, UK.
EClinicalMedicine
|January 8, 2026
概括
基于小组的药物遗传学 (PGx) 测试对于个性化医学来说成本效益有限. 预防性基因检测可以节省成本,支持将其整合到临床实践中,以改善患者的治疗结果.
科学领域:
- 药物遗传学和个性化医学
- 卫生经济学与研究成果研究成果
- 临床试验分析
背景情况:
- 药物遗传学 (PGx) 旨在个性化药物治疗,但需要临床实用性和成本效益的证据才能广泛采用.
- PREPARE研究此前已经证明了基于面板的PGx导向治疗在不同患者群体和适应症的临床实用性.
- 经济评估对于支持将PGx纳入常规医疗保健至关重要.
研究的目的:
- 提供关于PGx引导治疗的成本效益的经济证据.
- 从国家医疗保健系统的角度分析成本效益.
- 评估PGx测试对医疗保健成本和患者生活质量的影响.
主要方法:
- 多国性成本效益分析涉及PREPARE研究 (2017年3月至2020年6月) 的6930名患者.
- 从国家医疗保健系统的角度收集的数据,包括直接的医疗成本.
- 在多个时间点使用视觉模拟尺度 (VAS) 测量生活质量.
主要成果:
- 在每QALY11,000欧元的门上,PGx引导治疗的成本效益有限.
- 住院和药物不良反应 (ADR) 的成本是这两组人群的主要成本驱动因素.
- 预防性PGx测试,不包括测试费用,每名患者节省了大约103.6欧元的成本.
结论:
- 基于面板的PGx测试证明了成本效益,支持其在临床实践中的实施.
- 结合已证明的临床益处,这些发现提倡将PGx纳入常规医疗保健.
- PGx指导疗法为更有效和个性化的患者护理提供了一条途径.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
671
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
671
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
147
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
147
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
200
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
200
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
147
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
147
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
314
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
314